At the 14th International Conference on Endothelin: Physiology, Pathophysiology, and Therapeutics, researchers presented data on treatment of Alzheimer’s dementia in rats with IRL-1620, a chemical that binds to endothelin B receptors.

Previous studies had shown endothelin B receptors were important in brain development. Researchers set out to stimulate endothelin B receptors by intravenous (IV) injection of IRL-1620 to prevent and repair damage to the brain. When they administered IRL-1620 in rats with Alzheimer’s dementia, they saw an improvement in memory deficit by 50–60% and a reduction in oxidative stress by 45–50%. Treatment with IRL-1620 boosted certain recovery processes within the damaged brain, which resulted in more new blood vessels and neuronal cells.

RELATED: New Memory Test May Help ID At-Risk Patients for Alzheimer’s

This was the first study to indicate that selective stimulation of the endothelin B receptors by IV IRL-1620 improved memory, reduced oxidative stress, and enhanced neurovascular remodeling in animal mode of Alzheimer’s dementia, study authors concluded.

For more information visit